Jacobus Pfisterer - Concepedia

Author

Jacobus Pfisterer

Also Known As

Andreas du Bois, D Schmidt, J Pfisterer, J. PFISTERER, J. PFisterer, J. Pfisterer, J. Pfisterer, Jacobus Pfisterer, Jacobus Pﬁsterer, Pfisterer, J

325

Publications

8.3K

Citations

H-Index

Concepts

All Affiliations

University of Lübeck University Hospital Schleswig-Holstein Kliniken Essen-Mitte Helios Dr. Horst Schmidt Kliniken Wiesbaden Clinical Research Center Kiel

About

Jacobus Pfisterer is an author at University of Lübeck specializing in medicine, obstetrics, and ovarian cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	54	3.2K
2	Health Sciences	8	8	246
3	Public Health	2	2	64
4	Engineering	1	1	112
5	Biostatistics	1	1	42

Jacobus Pfisterer

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG Jacobus Pfisterer, Marie Plante, Ignace Vergote, Journal of Clinical Oncology	2006	746
Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial Philipp Harter, Andreas du Bois, Maik Hahmann, Annals of Surgical Oncology Gynecologic SurgerySurgical OncologyGynecological SurgeryMedicineDesktop Ovar Trial	2006	415
Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study Alexander Burges, Pauline Wimberger, Carolin Kümper, Clinical Cancer Research	2007	253
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase Jacek Grabowski, Philipp Harter, Florian Heitz, Gynecologic Oncology MedicineCancer ManagementChemotherapy ResponsivenessGynecologyAgo Study Group	2016	219
Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO Jacobus Pfisterer, B. Weber, Rainer Kimmig, JNCI Journal of the National Cancer Institute	2006	208
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial Andreas du Bois, Gunnar B. Kristensen, Isabelle Ray‐Coquard, The Lancet Oncology Placebo-controlled Phase 3MedicineMetronomic TherapyGynecologyStandard First-line Chemotherapy	2015	207
Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens Andreas du Bois, B. Weber, Justine Rochon, Journal of Clinical Oncology	2006	196
Potential Role of Lymphadenectomy in Advanced Ovarian Cancer: A Combined Exploratory Analysis of Three Prospectively Randomized Phase III Multicenter Trials Andreas du Bois, Philipp Harter, Éric Pujade-Lauraine, Journal of Clinical Oncology	2010	191
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial Jacobus Pfisterer, Catherine Shannon, Klaus Baumann, The Lancet Oncology MedicineMetronomic TherapyGynecologyRecurrent Ovarian CancerCancer Treatment	2020	157
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions Amer Karam, Jonathan A. Ledermann, Jae‐Weon Kim, Annals of Oncology MedicineGynecologic Cancer IntergroupCancer ManagementGynecologyCancer Treatment	2017	149

Page 1